Shaveta Vinayak
Academic Appointments
- Instructor, Medicine - Oncology
Key Documents
Contact Information
-
Clinical Offices
Stanford Women�s Cancer Center 900 Blake Wilbur Stanford, CA 94305 Tel Work (650) 498-6004 Fax (650) 490-7237
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Breast Cancer
- Oncology
- Triple-negative breast cancer
- BRCA-associated breast cancer
- Locally advanced breast cancer
Honors and Awards
- Member, Alpha Omega Alpha Honor Society (2004)
- Outstanding House Officer in Internal Medicine, Albert Einstein College of Medicine (2007)
- Henzl-Gabor Travel Fellowship, Stanford University (2010)
- Katherine McCormick Postdoctoral Fellowship Award, Stanford University (2010)
- Young Investigator Award, American Society of Clinical Oncology (2010)
- AACR-GlaxoSmithKline Outstanding Clinical Scholar Award, American Association for Cancer Research (2013)
Professional Education
| Internship: | Montefiore Medical Center - Albert Einstein College of Medicine NY (2005) |
| Residency: | Montefiore Medical Center - Albert Einstein College of Medicine NY (2007) |
| Medical Education: | Medical College of Virginia VA (2004) |
| Fellowship: | Stanford University CA (2010) |
| Board Certification: | General Internal Medicine, American Board of Internal Medicine (2007) |
| Board Certification: | Medical Oncology (2012) |
Scientific Focus
Current Research Interests
My research focuses on studying triple-negative breast cancer biology and identifying targeted treatment strategies. I am interested in designing breast cancer clinical trials with strong translational endpoints so that we can identify a subset of patients who benefit the most from the targeted treatment. Other interests include, prevention strategies for hormone receptor-negative breast cancer and survivorship issues.
Clinical Trials
- Recruiting A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer
- Not Recruiting A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
- Recruiting The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
- Recruiting A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
- Recruiting A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Publications
- mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park). 2013; (1): 38-44, 46, 48 passim
- PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Curr Breast Cancer Rep. 2010; (4): 190-197
- Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Curr Breast Cancer Rep. 2009; (3): 148-156
- Dual regulation of Akt/protein kinase B by heterotrimeric G protein subunits. J Biol Chem. 2000; (49): 38870-6
Help